Stockscreener 앱 받기
33.65
2.64%
0.865
시간 외 거래:
33.65
0.005
+0.01%
전일 마감가:
$32.78
열려 있는:
$33.22
하루 거래량:
2.00M
Relative Volume:
1.16
시가총액:
$4.61B
수익:
$705.14M
순이익/손실:
$-453.90M
주가수익비율:
-11.07
EPS:
-3.04
순현금흐름:
$-551.29M
1주 성능:
+13.13%
1개월 성능:
+24.20%
6개월 성능:
-13.29%
1년 성능:
-19.84%
1일 변동 폭
$32.97
$33.98
1주일 범위
$29.42
$33.98
52주 변동 폭
$23.95
$52.34
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
명칭
Ionis Pharmaceuticals Inc
전화
(760) 931-9200
주소
2855 GAZELLE COURT, CARLSBAD, CA
IONS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
33.65 | 4.61B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-07 | 개시 | H.C. Wainwright | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Neutral |
| 2024-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | 재개 | Jefferies | Buy |
| 2024-06-14 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 개시 | Raymond James | Strong Buy |
| 2023-07-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-06-07 | 재개 | Piper Sandler | Overweight |
| 2023-05-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2022-12-21 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 재개 | Morgan Stanley | Overweight |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-01 | 개시 | Citigroup | Sell |
| 2022-03-01 | 개시 | Guggenheim | Buy |
| 2022-02-01 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-14 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | 업그레이드 | UBS | Sell → Neutral |
| 2021-03-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 개시 | UBS | Sell |
| 2020-12-15 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-09-02 | 개시 | The Benchmark Company | Hold |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-11-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 재확인 | Stifel | Hold |
| 2018-08-07 | 재확인 | Stifel | Hold |
| 2018-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 재개 | Goldman | Sell |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-08-09 | 재확인 | Stifel | Hold |
| 2017-03-10 | 다운그레이드 | Goldman | Neutral → Sell |
| 2016-12-28 | 재확인 | BMO Capital Markets | Outperform |
| 2016-12-27 | 재확인 | Leerink Partners | Mkt Perform |
모두보기
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Spinocerebellar Ataxias Pipeline 2025: Comprehensive - openPR.com
Oligonucleotide Delivery System Market Key Players Analysis - openPR.com
Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasts - Yahoo Finance
Ionis Pharmaceuticals targets $750M revenue for 2025 with multiple launches underway - MSN
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View - MSN
Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4) - Quantisnow
Ionis Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Analysts Just Shipped A Substantial Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Estimates - simplywall.st
Earnings call transcript: Ionis Pharmaceuticals beats Q1 2025 forecasts - Investing.com Australia
Ionis Pharmaceuticals (IONS) Projects Revenue Growth with TRYNGO - GuruFocus
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates - MSN
Ionis Pharmaceuticals (IONS) Target Price Adjusted by Guggenheim - GuruFocus
Polycythemia vera Market: Epidemiology, Therapies, - openPR.com
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 13 Experts - Benzinga
Ionis Pharmaceuticals (IONS) Target Price Increased to $50 After Strong Q1 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals Ups Revenue Forecast After Q1 Success - Finimize
Ionis Pharmaceuticals Lifts Revenue Forecast After Strong Q1, Oppenheimer Says - marketscreener.com
IONIS: Guggenheim Maintains Buy Rating but Lowers Price Target | - GuruFocus
Ionis Pharmaceuticals (IONS) Receives Price Target Boost from HC Wainwright | IONS Stock News - GuruFocus
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2025 Earnings Call Transcript - Insider Monkey
Ionis Pharmaceuticals (IONS) Target Price Adjusted by Guggenheim | IONS Stock News - GuruFocus
Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo
Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlight - GuruFocus
Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Ionis Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Ionis Pharmaceuticals: Q1 Earnings Snapshot - MySA
Ionis Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges - TipRanks
Ionis Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Ionis Pharmaceuticals (IONS) Boosts 2025 Revenue Guidance and St - GuruFocus
Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge - Benzinga
Earnings call transcript: Ionis Pharmaceuticals beats Q1 2025 forecasts By Investing.com - Investing.com India
Novartis to acquire Regulus in deal for kidney disease drug - BioPharma Dive
Ionis Pharmaceuticals (IONS) Q1 2025 Earnings: Revenue Surpasses - GuruFocus
Ionis Pharmaceuticals Reports First Quarter 2025 Financial Results - TradingView
Ionis Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Ionis Pharmaceuticals Q1 Net Loss Narrows as Revenue Increases; 2025 Revenue Guidance Raised - marketscreener.com
Ionis reports first quarter 2025 financial results - BioSpace
Ionis (IONS) Sees Strong Q1 Revenue with New Launches Fueling Gr - GuruFocus
IONIS PHARMACEUTICALS Earnings Results: $IONS Reports Quarterly Earnings - Nasdaq
Ionis reports first quarter 2025 financial results | IONS Stock News - GuruFocus
Earnings Flash (IONS) Ionis Pharmaceuticals Posts Q1 EPS Loss $0.93, vs. FactSet Est of $1.10 Loss - marketscreener.com
Polycythemia Clinical Trials, Drugs, Key Companies, - openPR.com
New Harris Poll findings reveal HAE patients are unsatisfied wit - GuruFocus
New Harris Poll: 91% of HAE Patients Desperate for Better Treatments as Current Options Fall Short - Stock Titan
Familial Lipoprotein Lipase Deficiency Market Trends, Size, - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Ionis Pharmaceuticals, Inc. and Akcea Therapeutics Announces the Final Study Results from NEURO-TTR, the Pivotal Study of TEGSEDI™ - marketscreener.com
Familial Amyloid Cardiomyopathy Treatment Market Future - openPR.com
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):